Certara, a leading provider of drug discovery and development software and scientific consulting services, announced that it has released a new version of Phoenix, the industry leading PK/PD modeling software platform that is used by more than 4,000 researchers at 2,000 institutions, including the FDA.
All Phoenix tools are accessed within a single graphical user interface for ease of use and can be used individually or together. Certara continues to offer free upgrades to the Phoenix products for all currently licensed users. The newly available products include:
â€śThis release of Phoenix represents a very important milestone. In addition to releasing the first commercial implementation of the Quasi-Random Parametric Expectation Maximization (QRPEM) algorithm for population PK/PD modeling, this version of Phoenix adds critical infrastructure improvements, usability enhancements and improved linkage with third-party tools,â€ť said Daniel Weiner, Ph.D., Senior Vice President and General Manager of Certara.
â€śThe strong adoption of Phoenix by the industry over the last three years has been very gratifying,â€ť continued Dr. Weiner. â€śMany organizations are now building and sharing re-usable workflows within Phoenix to meet the demand of improved efficiency. Even less experienced users are able to quickly perform analysis in a consistent and repeatable manner. Phoenix has evolved into a single integrated platform that can support the needs of pre-clinical DMPK, clinical pharmacology and formulations departments, allowing it to truly support translational science approaches to drug development.â€ť
Key Developments included in the new release include:
Certaraâ„˘ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp, a research-based company providing predictive pharmacokinetic and pharmacodynamicÂ tools,Â workshopsÂ andÂ consultancyÂ services; and PharsightÂ® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development.Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation and scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com.Business Wire
Last updated on: 10/04/2012